Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N²M²: Targeted Therapies + RT in Glioblastoma
NCT03158389Phase 2Completed
- Sponsor
- Heidelberg University Hospital
- Start
- May 2018
- Primary completion
- Feb 2023
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, open-label trial of asunercept, alectinib, idasanutlin, atezolizumab, vismodegib and 2 more in glioblastoma (GBM) (8 arms), sponsored by Heidelberg University Hospital. Primary endpoint: Progression-Free Survival Rate at 6 Months. Started May 2018; status: completed.
02
Drugs
asunerceptalectinibidasanutlinatezolizumabvismodegib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03158389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03158389.